HWM
IONS icon

HB Wealth Management’s Ionis Pharmaceuticals IONS Stock Holding History

HB Wealth Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$240K Buy
3,025
+99
+3% +$7.45K ﹤0.01% 1498
2026
Q1 		$220K Buy
2,926
+4
+0.1% +$316 ﹤0.01% 1385
2025
Q4 		$231K Buy
+2,922
New +$220K ﹤0.01% 1275

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

HB Wealth Management's IONS Position: Q2 2026 in Review

HB Wealth Management increased its Ionis Pharmaceuticals (IONS) stake by 3.4% in Q2 2026, buying an estimated $7.45K and bringing the position to 3,025 shares worth $240K. The position accounts for ﹤0.01% of the portfolio, ranked #1498.

HB Wealth Management first reported a position in IONS in Q4 2025 and has held it in 3 quarters since. 515 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • HB Wealth Management held 3,025 shares of Ionis Pharmaceuticals worth $240K as of Q2 2026.
  • HB Wealth Management bought 99 Ionis Pharmaceuticals shares in Q2 2026, an estimated $7.45K.
  • Ionis Pharmaceuticals made up ﹤0.01% of HB Wealth Management's portfolio in Q2 2026, its #1498 holding.
  • HB Wealth Management first reported a position in Ionis Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 515 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on HB Wealth Management's 13F filing for Q2 2026, filed 29 Jul 2026.